+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Middle East & Africa Colorectal Cancer Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Modality and End User

  • PDF Icon

    Report

  • 162 Pages
  • September 2022
  • Region: Africa, Middle East
  • The Insight Partners
  • ID: 5668319
UP TO OFF until Dec 31st 2024
The colorectal cancer market in the Middle East & Africa is expected to grow from US$ 885.81 million in 2022 to US$ 1,076.92 million by 2028; it is estimated to grow at a CAGR of 2.5% from 2022 to 2028.

Numerous benefits offered by generic drugs is among the major factor driving the growth of the Middle East & Africa colorectal cancer market. Generic drugs are alternatives to branded drugs. The pharmacological effects of generic drugs are similar to their branded counterparts. Generic drugs are cost-effective as the manufacturers do not invest in developing and marketing a new drug. After the expiry of a drug patent, other manufacturers apply for FDA approval of a generic intended for its manufacturing and selling. Thus, generic drugs are cheaper than their branded counterparts. Generic drugs have the same dosage, effects and side effects, route of administration, risks, safety, and strength as the original branded drugs.

Generic drugs are important in oncology because some anticancer drugs are only offered as generics. Patients are likely to abandon branded prescriptions associated with their higher prices. Generic drugs for cancer treatment are profitable for manufacturers and patients due to their affordability and efficacy, especially in developing countries in the Middle East & Africa, where the paying capacity of consumers is relatively low. Thus, the preference for generic drugs among consumers and the high adoption of generic drugs for colorectal cancer treatment are fueling the growth of the colorectal cancer market in the region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Middle East & Africa colorectal cancer market at a substantial CAGR during the forecast period.

Middle East & Africa Colorectal Cancer Market Segmentation

The Middle East & Africa colorectal cancer market is segmented into modality, end user, and country.
  • Based on modality, the Middle East & Africa colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period.
  • Based on end user, the Middle East & Africa colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share.
  • Based on country, the Middle East & Africa colorectal cancer market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held the largest market share in 2022.
Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the Middle East & Africa colorectal cancer market.

Table of Contents

1. Introduction
1.1 Scope of the Study.
1.2 The Insight Partners Research Report Guidance.
1.3 Market Segmentation
1.3.1 MEA Colorectal Cancer Market - By Modality.
1.3.2 MEA Colorectal Cancer Market - By End User
1.3.3 MEA Colorectal Cancer Market - By Country
2. MEA Colorectal Cancer Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Colorectal Cancer- Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinion
5. MEA Colorectal Cancer Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Colorectal Cancer
5.1.2 New Product Launches
5.1.3 Benefits Offered by Generic Drugs
5.2 Market Restraints
5.2.1 Pricing Pressure on Drug Manufacturers
5.3 Future Trends
5.3.1 Inclination Toward Personalized Medicine
5.4 Impact Analysis
6. MEA Colorectal Cancer Market- MEA Analysis
6.1 MEA Colorectal Cancer Market Revenue Forecast and Analysis
7. MEA Colorectal Cancer Market Analysis - By Modality
7.1 Overview
7.2 MEA Colorectal Cancer Market Revenue Share, By Modality 2022 & 2028 (%)
7.3 Diagnosis Type
7.3.1 Overview
7.3.2 Diagnosis Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.3 Immunohistochemistry
7.3.3.1 Overview
7.3.3.2 Immunohistochemistry: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.4 Stool Test
7.3.4.1 Overview
7.3.4.2 Stool Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.5 Flexible Sigmoidoscopy
7.3.5.1 Overview
7.3.5.2 Flexible Sigmoidoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.6 Colonoscopy
7.3.6.1 Overview
7.3.6.2 Colonoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.7 CEA Test
7.3.7.1 Overview
7.3.7.2 CEA Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.8 Other Test
7.3.8.1 Overview
7.3.8.2 Other Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Therapy Type
7.4.1 Overview
7.4.2 MEA Therapy Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3 Chemotherapy
7.4.3.1 Overview
7.4.3.2 Chemotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3.3 Alkylating Agent
7.4.3.3.1 Overview
7.4.3.3.2 Alkylating Agent: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3.4 Antimetabolites
7.4.3.4.1 Antimetabolites: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3.5 Others
7.4.3.5.1 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4 Immunotherapy
7.4.4.1 Overview
7.4.4.2 Immunotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.3 Panitumumab.
7.4.4.3.1 Overview
7.4.4.3.2 Panitumumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.4 Cetuximab.
7.4.4.4.1 Overview
7.4.4.4.2 Cetuximab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.5 Bevacizumab
7.4.4.5.1 Overview
7.4.4.5.2 Bevacizumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.6 Others
7.4.4.6.1 Overview
7.4.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.5 Chemoprotectant
7.4.5.1 Overview
7.4.5.2 Chemoprotectant: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.6 Others.
7.4.6.1 Overview
7.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Imaging Type
7.5.1 Overview
7.5.2 MEA Imaging Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5.3 Computed Tomography (CT)
7.5.3.1 Overview
7.5.3.2 Computed Tomography (CT): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5.4 Magnetic Resonance Imaging (MRI)
7.5.4.1 Overview
7.5.4.2 Magnetic Resonance Imaging (MRI): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others
7.5.5.1 Overview
7.5.5.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
8. MEA Colorectal Cancer Market Revenue and Forecast To 2028 - By End User
8.1 Overview
8.2 MEA Colorectal Cancer Market Revenue Share, By End User 2022 & 2028 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Diagnostic and Research Laboratories.
8.4.1 Overview.
8.4.2 Diagnostic and Research Laboratories: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9. MEA Colorectal Cancer Market Revenue and Forecast to 2028 - Country Analysis
9.1 Overview.
9.1.1 MEA Colorectal Cancer Market Revenue and Forecasts to 2028, By Country (%)
9.1.1.1 UAE Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
9.1.1.1.1 UAE Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
9.1.1.1.2 UAE: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.1.1.2.1 UAE: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
9.1.1.1.2.2 UAE: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
9.1.1.1.2.2.1 UAE: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
9.1.1.1.2.2.2 UAE: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
9.1.1.1.2.3 UAE: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
9.1.1.1.3 UAE : Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.1.1.2 Saudi Arabia Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.1.1.2.1 Saudi Arabia Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
9.1.1.2.2 Saudi Arabia: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.1.2.2.1 Saudi Arabia: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
9.1.1.2.2.2 Saudi Arabia: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
9.1.1.2.2.2.1 Saudi Arabia: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
9.1.1.2.2.2.2 Saudi Arabia: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
9.1.1.2.2.3 Saudi Arabia: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
9.1.1.2.3 Saudi Arabia: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.1.1.3 South Africa Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
9.1.1.3.1 South Africa Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
9.1.1.3.2 South Africa: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.1.3.2.1 South Africa: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
9.1.1.3.2.2 South Africa: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
9.1.1.3.2.2.1 South Africa: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
9.1.1.3.2.2.2 South Africa: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
9.1.1.3.2.3 South Africa: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
9.1.1.3.3 South Africa: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.1.1.4 Rest of MEA: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)
9.1.1.4.1 Overview.
9.1.1.4.2 Rest of MEA: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)
9.1.1.4.3 Rest of MEA: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.1.4.3.1 Rest of MEA:: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
9.1.1.4.3.2 Rest of MEA: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
9.1.1.4.3.2.1 Rest of MEA: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
9.1.1.4.3.2.2 Rest of MEA: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
9.1.1.4.3.3 Rest of MEA: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
9.1.1.4.4 Rest of MEA: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
10. Colorectal Cancer Market - Industry Landscape
10.1 Overview..
10.2 Growth Strategies In The Colorectal Cancer Market, 2022-2028.
10.3 Organic Developments.
10.3.1 Overview..
10.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2022-2028.
10.4 Inorganic Developments.
10.4.1 Overview..
10.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2022-2028.
11. Company Profiles
11.1 Epigenomics AG..
11.1.1 Key Facts.
11.1.2 Business Description.
11.1.3 Products and Services.
11.1.4 Financial Overview..
11.1.5 SWOT Analysis.
11.1.6 Key Developments.
11.2 Abbott
11.2.1 Key Facts.
11.2.2 Business Description.
11.2.3 Products and Services.
11.2.4 Financial Overview..
11.2.5 SWOT Analysis.
11.2.6 Key Developments
11.3 Amgen Inc.
11.3.1 Key Facts.
11.3.2 Business Description.
11.3.3 Products and Services.
11.3.4 Financial Overview..
11.3.5 SWOT Analysis.
11.3.6 Key Developments.
11.4 F. HOFFMANN-LA ROCHE LTD.
11.4.1 Key Facts.
11.4.2 Business Description.
11.4.3 Products and Services.
11.4.4 Financial Overview..
11.4.5 SWOT Analysis.
11.4.6 Key Developments.
11.5 Bruker Corporation.
11.5.1 Key Facts.
11.5.2 Business Description.
11.5.3 Products and Services.
11.5.4 Financial Overview..
11.5.5 SWOT Analysis.
11.5.6 Key Developments.
11.6 Quest Diagnostics Incorporated.
11.6.1 Key Facts.
11.6.2 Business Description.
11.6.3 Products and Services.
11.6.4 Financial Overview..
11.6.5 SWOT Analysis.
11.6.6 Key Developments.
11.7 Volitionrx Limited.
11.7.1 Key Facts.
11.7.2 Business Description.
11.7.3 Products and Services.
11.7.4 Financial Overview..
11.7.5 SWOT Analysis.
11.7.6 Key Developments.
12. Appendix
12.1 About The Insight Partners.
12.2 Glossary of Terms.

Companies Mentioned

  • Abbott
  • Amgen Inc.
  • Bruker Corporation
  • Epigenomics AG
  • F. Hoffmann-La Roche AG
  • Quest Diagnostics
  • VolitionRx Limited

Table Information